MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
Adaptimmune Therapeutics plc EV - Enterprise Value 2011-2026 | ADAP
Annual EV - Enterprise Value Adaptimmune Therapeutics plc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.15 B | 1.4 B | 2.84 B | 4.72 B | 2.52 T | 2.72 T | 4.57 T | 1.78 T | 6.25 B | 53.1 M | 3.97 M | 4.09 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.57 T | 3.97 M | 968 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Xeris Pharmaceuticals
XERS
|
1.23 B | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
1.12 B | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
1.17 B | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
GT Biopharma
GTBP
|
-2.9 M | $ 0.47 | -2.41 % | $ 892 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
1.22 B | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-75.9 M | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | Israel |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.65 B | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
3.14 B | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
59.3 B | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
444 M | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Entera Bio Ltd.
ENTX
|
25.6 M | $ 1.38 | -0.72 % | $ 63.3 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
442 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
Teligent, Inc.
TLGT
|
4.75 B | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Evogene Ltd.
EVGN
|
9.72 M | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
5.37 B | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
5.88 B | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
394 B | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
6.74 B | - | - | $ 8.14 B | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
AIM ImmunoTech
AIM
|
-6.86 M | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
9.45 M | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
3.01 B | $ 20.67 | -1.38 % | $ 2.61 B | USA |